Algreen

These figures are as of March 31, 2024. The EV/Sales ratio of 116.52 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Algreen trades at an EV/FCF ratio of 0.19, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of March 31, 2024, Algreen maintains a current ratio of 1.80, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -305.21, indicating conservative leverage, while an interest coverage ratio of -0.22 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2024, Algreen posted a negative return on equity (ROE) of -594.50, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -362.45, reflecting losses generated across the asset base. Inventory turnover of 0.86 indicates how many times Algreen sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 14, 2024, Algreen's stock has declined approximately 97.13% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Over the twelve months ended March 31, 2024, Algreen posted a gross margin of -1,205.36, reflecting its pricing power and cost economics. The operating margin of -13,784.46 and net profit margin of -77,209.19 provide insight into operational efficiency.

Algreen's most recent stock split took place on August 22, 2023 with a 800:1 split ratio.

As of March 31, 2024, Algreen has an Altman Z-Score of 133.40, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.